Clinical value of molecular MRD monitoring by next-generation sequencing in patients with IDH2 mutated AML.

Shumilov, Evgenii; Flach, Johanna; Joncourt, Raphael; Porret, Naomi; Wiedemann, Gertrud; Novak, Urban; Gfeller, Eva; Jeker, Barbara; Amstutz, Ursula; Pabst, Thomas; Bacher, Vera (2019). Clinical value of molecular MRD monitoring by next-generation sequencing in patients with IDH2 mutated AML. Leukemia & lymphoma, 60(10), pp. 2588-2590. Taylor & Francis 10.1080/10428194.2019.1585838

Full text not available from this repository. (Request a copy)

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Institute of Clinical Chemistry
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Joncourt, Raphael; Porret, Naomi; Wiedemann, Gertrud; Novak, Urban; Jeker, Barbara; Amstutz, Ursula; Pabst Müller, Thomas Niklaus and Bacher, Vera Ulrike

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1029-2403

Publisher:

Taylor & Francis

Language:

English

Submitter:

Rebeka Gerber

Date Deposited:

01 Nov 2019 15:10

Last Modified:

01 May 2020 16:25

Publisher DOI:

10.1080/10428194.2019.1585838

PubMed ID:

30998101

URI:

https://boris.unibe.ch/id/eprint/134266

Actions (login required)

Edit item Edit item
Provide Feedback